The iron hypothesis of atherosclerosis and its clinical impact

Annals of Medicine

Volumn 35, Issue 8, 2003, Pages 578-591

  Yuan, Xi Ming ^a   Li, Wei ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Atherosclerosis; Iron depletion; Mild iron overload; Models; Tissue iron

Indexed keywords

ACETYLSALICYLIC ACID; ADENOVIRUS VECTOR; ALPHA TOCOPHEROL; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DEFERIPRONE; DEFEROXAMINE; FERRITIN; FERROUS SULFATE; HEME OXYGENASE 1; ICFR 187; IRON; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; RAZOXANE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD DONOR; CORONARY RISK; DEMOGRAPHY; EPIDEMIOLOGICAL DATA; GENE MUTATION; HEART MUSCLE REPERFUSION; HEMOCHROMATOSIS; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; INCIDENCE; IRON CHELATION; IRON DEFICIENCY ANEMIA; IRON INTAKE; IRON OVERLOAD; IRON STORAGE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIPID OXIDATION; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION; PHLEBOTOMY; PRIORITY JOURNAL; REDUCTION; REVIEW; SEX DIFFERENCE; SICKLE CELL ANEMIA; THALASSEMIA; VIRAL GENE DELIVERY SYSTEM;

ARTERIOSCLEROSIS; CLINICAL TRIALS; HUMANS; IRON; IRON OVERLOAD; OXIDATION-REDUCTION; SEX CHARACTERISTICS;

EID: 0348107413     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/07853890310016342     Document Type: Review

References (159)

1. Hughes S. Novel risk factors for coronary heart disease: emerging connections. J Cardiovasc Nurs 2000;14:91-103.
2. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981;1:1293-4.
3. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976;85:447-52.
4. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
5. Herrington DM. The HERS trial results: paradigms lost? Heart and Estrogen/progestin Replacement Study. Ann Intern Med 1999;131:463-6.
6. Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 2000;140: 98-104.
7. Cogswell ME, Burke W, McDonnell SM, Franks AL. Screening for hemochromatosis. A public health perspective. Am J Prev Med 1999;16:134-40.
8. Cook JD, Skikne BS, Lynch SR, Reusser ME. Estimates of iron sufficiency in the US population. Blood 1986;68:726-31.
9. Holmstrom P, Marmur J, Eggertsen G, Gafvels M, Stal P. Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls. Gut 2002;51:723-30.
10. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997;34:275-8.
11. Milman N, Byg KE, Ovesen L, Kirchhoff M, Jurgensen KS. Iron status in Danish men 1984-1994: a cohort comparison of changes in iron stores and the prevalence of iron deficiency and iron overload. Eur J Haematol 2002;68:332-40.
12. Meyers DG. The iron hypothesis: does iron cause atherosclerosis? Clin Cardiol 1996;19:925-9.
13. Corti MC, Gaziano M, Hennekens CH. Iron status and risk of cardiovascular disease. Ann Epidemiol 1997;7:62-8.
14. Chau LY. Iron and atherosclerosis. Proceedings of the National Science Council, Republic of China, Part B. Life Sciences 2000;24:151-5.
15. Yuan XM, Brunk UT. Iron and LDL-oxidation in atherogenesis. APMIS 1998;106:825-42.
16. de Valk B, Marx JJ. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med 1999;159:1542-8.
17. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 1978;89:157-61.
18. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992;86:803-11.
19. Salonen JT, Nyyssonen K, Salonen R. Body iron stores and the risk of coronary heart disease. N Engl J Med 1994;331: 1159, discussion 1160.
20. Tuomainen TP, Punnonen K, Nyyssonen K, Salonen JT. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 1998;97:1461-6.
21. Kiechl S, Willeit J. The natural course of atherosclerosis. Part I: incidence and progression. Arterioscler Thromb Vasc Biol 1999;19:1484-90.
22. Tuomainen TP, Kontula K, Nyyssonen K, Lakka TA, Helio T, Salonen JT. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland. Circulation 1999;100:1274-9.
23. Roest M, van der Schouw YT, de Valk B, Marx JJ, Tempelman MJ, de Groot PG, et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 1999;100:1268-73.
24. Sempos CT. Do body iron stores increase the risk of developing coronary heart disease? Am J Clin Nutr 2002; 76:501-3.
25. Ma J, Stampfer MJ. Body iron stores and coronary heart disease. Clin Chem 2002;48:601-3.
26. Berge LN, Bonaa KH, Nordoy A. Serum ferritin, sex hormones, and cardiovascular risk factors in healthy women. Arterioscler Thromb 1994;14:857-61.
27. Milman N, Kirchhoff M. Relationship between serum ferritin and risk factors for ischaemic heart disease in 2235 Danes aged 30-60 years. J Intern Med 1999;245:423-33.
28. Rossi E, McQuillan BM, Hung J, Thompson PL, Kuek C, Beilby JP. Serum ferritin and C282Y mutation of the hemochromatosis gene as predictors of asymptomatic carotid atherosclerosis in a community population. Stroke 2000;31: 3015-20.
29. Ramakrishnan U, Kuklina E, Stein AD. Iron stores and cardiovascular disease risk factors in women of reproductive age in the United States. Am J Clin Nutr 2002;76:1256-60.
30. Dubick MA, Hunter GC, Casey SM, Keen CL. Aortic ascorbic acid, trace elements, and superoxide dismutase activity in human aneurysmal and occlusive disease. Proc Soc Exp Biol Med 1987;184:138-43.
31. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J 1992;286:901-5.
32. Swain J, Gutteridge JM. Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material. FEBS Lett 1995;368:513-5.
33. Thong PS, Selley M, Watt F. Elemental changes in atherosclerotic lesions using nuclear microscopy. Cell Mol Biol 1996;42:103-10.
34. Yuan XM, Li W, Olsson AG, Brunk UT. Iron in human atheroma and LDL oxidation by macrophages following erythrophagocytosis. Atherosclerosis 1996;124:61-73.
35. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 1996;97:1535-44.
36. Sorenson E, Skiles EH, Xu B, Aleryani S, Kostka P. Role of redox-active iron ions in the decomposition of S- nitrosocysteine in subcellular fractions of porcine aorta. Eur J Biochem 2000;267:4593-9.
37. Yuan XM. Apoptotic macrophage-derived foam cells of human atheromas are rich in iron and ferritin, suggesting iron-catalysed reactions to be involved in apoptosis. Free Radic Res 1999;30:221-31.
38. Pang JH, Jiang MJ, Chen YL, Wang FW, Wang DL, Chu SH, et al. Increased ferritin gene expression in atherosclerotic lesions. J Clin Invest 1996;97:2204-12.
39. Garner B, Li W, Roberg K, Brunk UT. On the cytoprotective role of ferritin in macrophages and its ability to enhance lysosomal stability. Free Radic Res 1997;27:487-500.
40. Brasen JH, Kivela A, Roser K, Rissanen TT, Niemi M, Luft FC, et al. Angiogenesis, vascular endothelial growth factor and platelet-derived growth factor-BB expression, iron deposition, and oxidation-specific epitopes in stented human coronary arteries. Arterioscler Thromb Vasc Biol 2001;21: 1720-6.
41. Schmitz SA, Coupland SE, Gust R, Winterhalter S, Wagner S, Kresse M, et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol 2000;35:460-71.
42. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 2001;103:415-22.
43. Schmitz SA, Taupitz M, Wagner S, Coupland SE, Gust R, Nikolova A, et al. Iron-oxide-enhanced magnetic resonance imaging of atherosclerotic plaques: postmortem analysis of accuracy, inter-observer agreement, and pitfalls. Invest Radiol 2002;37:405-11.
44. Schmitz SA, Taupitz M, Wagner S, Wolf KJ, Beyersdorff D, Hamm B. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging 2001;14:355-61.
45. Sochaski MA, Bartfay WJ, Thorpe SR, Baynes JW, Bartfay E, Lehotay DC, et al. Lipid peroxidation and protein modification in a mouse model of chronic iron overload. Metabolism 2002;51:645-51.
46. Araujo JA, Romano EL, Brito BE, Parthe V, Romano M, Bracho M, et al. Iron overload augments the development of atherosclerotic lesions in rabbits. Arterioscler Thromb Vasc Biol 1995;15:1172-80.
47. Meijer GW, Beems RB, Janssen GB, Vaessen HA, Speijers GJ. Cadmium and atherosclerosis in the rabbit: reduced atherogenesis by superseding of iron? Food Chem Toxicol 1996;34:611-21.
48. van Jaarsveld H, Pool GF, Barnard HC. Dietary iron concentration alters LDL oxidatively. The effect of antioxidants. Res Commun Mol Pathol Pharmacol 1998;99:69-80.
49. Van Lenten BJ, Prieve J, Navab M, Hama S, Lusis AJ, Fogelman AM. Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. J Clin Invest 1995;95:2104-10.
50. Ponraj D, Makjanic J, Thong PS, Tan BK, Watt F. The onset of atherosclerotic lesion formation in hypercholesterolemic rabbits is delayed by iron depletion. FEBS Lett 1999;459:218-22.
51. Young PB, Kennedy S, Molloy AM, Scott JM, Weir DG, Kennedy DG. Lipid peroxidation induced in vivo by hyperhomocysteinaemia in pigs. Atherosclerosis 1997;129: 67-71.
52. Lee TS, Shiao MS, Pan CC, Chau LY. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation 1999;99:1222-9.
53. Juan SH, Lee TS, Tseng KW, Liou JY, Shyue SK, Wu KK, et al. Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001;104:1519-25.
54. Dabbagh AJ, Shwaery GT, Keaney JF, Jr, Frei B. Effect of iron overload and iron deficiency on atherosclerosis in the hypercholesterolemic rabbit. Arterioscler Thromb Vasc Biol 1997;17:2638-45.
55. Kirk EA, Heinecke JW, LeBoeuf RC. Iron overload diminishes atherosclerosis in apoE-deficient mice. J Clin Invest 2001;107:1545-53.
56. Turbino-Ribeiro SM, Silva ME, Chianca DA, Jr, De Paula H, Cardoso LM, Colombari E, et al. Iron overload in hypercholesterolemic rats affects iron homeostasis and serum lipids but not blood pressure. J Nutr 2003;133:15-20.
57. Johnson MA, Fischer JG, Bowman BA, Gunter EW. Iron nutriture in elderly individuals. FASEB J 1994;8:609-21.
58. Looker AC, Gunter EW, Cook JD, Green R, Harris JW. Comparing serum ferritin values from different population surveys. Vital Health Stat 2 1991;111:1-19.
59. Garry PJ, Goodwin JS, Hunt WC. Iron status and anemia in the elderly: new findings and a review of previous studies. J Am Geriatr Soc 1983;31:389-99.
60. Fleming DJ, Jacques PF, Tucker KL, Massaro JM, D'Agostino RB, Sr., Wilson PW, et al. Iron status of the free-living, elderly Framingham Heart Study cohort: an iron-replete population with a high prevalence of elevated iron stores. Am J Clin Nutr 2001;73:638-46.
61. Fleming DJ, Tucker KL, Jacques PF, Dallal GE, Wilson PW, Wood RJ. Dietary factors associated with the risk of high iron stores in the elderly Framingham Heart Study cohort. Am J Clin Nutr 2002;76:1375-84.
62. Lynch SR, Finch CA, Monsen ER, Cook JD. Iron status of elderly Americans. Am J Clin Nutr 1982;36:1032-45.
63. Yoshida S, Takano Y, Moriwake Y, Tohno Y, Masuda M, Tohno S, et al. Increases of calcium and magnesium and decreases of phosphorus and iron with aging in human uterine tubes. Biol Trace Elem Res 2001;80:13-22.
64. Klipstein-Grobusch K, Koster JF, Grobbee DE, Lindemans J, Boeing H, Hofman A, et al. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr 1999;69:1231-6.
65. Kiechl S, Aichner F, Gerstenbrand F, Egger G, Mair A, Rungger G, et al. Body iron stores and presence of carotid atherosclerosis. Results from the Bruneck Study. Arterioscler Thromb 1994;14:1625-30.
66. Gillum RF, Mussolino ME, Madans JH. Coronary heart disease incidence and survival in African-American women and men. The NHANES I Epidemiologic Follow-up Study. Ann Intern Med 1997;127:111-8.
67. Sacco RL, Boden-Albala B, Gan R, Chen X, Kargman DE, Shea S, et al. Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol 1998;147:259-68.
68. Lubin IM, Yamada NA, Stansel RM, Pace RG, Rohlfs EM, Silverman LM. HFE genotyping using multiplex allele-specific polymerase chain reaction and capillary electrophor-esis. Arch Pathol Lab Med 1999;123:1177-81.
69. Gordeuk V, Mukiibi J, Hasstedt SJ, Samowitz W, Edwards CQ, West G, et al. Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med 1992; 326:95-100.
70. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001;154:193-206.
71. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24.
72. Steinberg KK, Cogswell ME, Chang JC, Caudill SP, McQuillan GM, Bowman BA, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001;285:2216-22.
73. Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996;335:1799-805.
74. Rasmussen ML, Folsom AR, Catellier DJ, Tsai MY, Garg U, Eckfeldt JH. A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2001;154:739-46.
75. Battiloro E, Ombres D, Pascale E, D'Ambrosio E, Verna R, Arca M. Haemochromatosis gene mutations and risk of coronary artery disease. Eur J Hum Genet 2000;8:389-92.
76. Datz C, Haas T, Rinner H, Sandhofer F, Patsch W, Paulweber B. Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: a protective role against iron deficiency? Clin Chem 1998;44:2429-32.
77. Whitfield JB, Cullen LM, Jazwinska EC, Powell LW, Heath AC, Zhu G, et al. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am J Hum Genet 2000;66: 1246-58.
78. Rossi E, Bulsara MK, Olynyk JK, Cullen DJ, Summerville L, Powell LW. Effect of hemochromatosis genotype and lifestyle factors on iron and red cell indices in a community population. Clin Chem 2001;47:202-8.
79. Beutler E. Genetic irony beyond haemochromatosis: clinical effects of HLA-H mutations. Lancet 1997;349:296-7.
80. Nassar BA, Zayed EM, Title LM, O'Neill BJ, Bata IR, Kirkland SA, et al. Relation of HFE gene mutations, high iron stores and early onset coronary artery disease. Can J Cardiol 1998;14:215-20.
81. Claeys D, Walting M, Julmy F, Wuillemin WA, Meyer BJ. Haemochromatosis mutations and ferritin in myocardial infarction: a case-control study. Eur J Clin Invest 2002;32 Suppl 1:3-8.
82. de Valk B, Addicks MA, Gosriwatana I, Lu S, Hider RC, Marx JJ. Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes. Eur J Clin Invest 2000;30:248-51.
83. Lekakis J, Papamicheal C, Stamatelopoulos K, Cimponeriu A, Voutsas A, Vemmos K, et al. Hemochromatosis associated with endothelial dysfunction: evidence for the role of iron stores in early atherogenesis. Vasc Med 1999;4:147-8.
84. Failla M, Giannattasio C, Piperno A, Vergani A, Grappiolo A, Gentile G, et al. Radial artery wall alterations in genetic hemochromatosis before and after iron depletion therapy. Hepatology 2000;32:569-73.
85. Niederau C. Iron overload and atherosclerosis. Hepatology 2000;32:672-4.
86. Say AE, Gursurer M, Yazicioglu MV, Ersek B. Impact of body iron status on myocardial perfusion, left ventricular function, and angiographic morphologic features in patients with hypercholesterolemia. Am Heart J 2002;143:257-64.
87. Livrea MA, Tesoriere L, Maggio A, D'Arpa D, Pintaudi AM, Pedone E. Oxidative modification of low-density lipoprotein and atherogenetic risk in beta-thalassemia. Blood 1998;92: 3936-42.
88. Tesoriere L, D'Arpa D, Maggio A, Giaccone V, Pedone E, Livrea MA. Oxidation resistance of LDL is correlated with vitamin E status in beta-thalassemia intermedia. Atherosclerosis 1998;137:429-35.
89. Altamentova SM, Marva E, Shaklai N. Oxidative interaction of unpaired hemoglobin chains with lipids and proteins: a key for modified serum lipoproteins in thalassemia. Arch Biochem Biophys 1997;345:39-46.
90. Brizzi P, Isaja T, D'Agata A, Malaguarnera L, Malaguarnera M, Musumeci S. Oxidized LDL antibodies (OLAB) in patients with beta-thalassemia major. J Atheroscler Thromb 2002;9:139-44.
91. Djoumessi S, Zekeng L, Lando G, Zeukeng D. Serum lipids and atherogenic risk in sickle-cell trait carriers. Ann Biol Clin 1994;52:663-5.
92. Erasmus RT, Olukoga AO, Ojuawo O. Plasma lipids and lipoproteins in Nigerian children with sickle cell anemia. Ann Trop Paediatr 1990;10:421-3.
93. Belcher JD, Marker PH, Geiger P, Girotti AW, Steinberg MH, Hebbel RP, et al. Low-density lipoprotein susceptibility to oxidation and cytotoxicity to endothelium in sickle cell anemia. J Lab Clin Med 1999;133:605-12.
94. Levey AS, Eknoyan G. Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant 1999;14:828-33.
95. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-92.
96. Shinzato T, Nakai S, Akiba T, Yamagami S, Yamazaki C, Kitaoka T, et al. Report of the annual statistical survey of the Japanese Society for Dialysis Therapy in 1996. Kidney Int 1999;55:700-12.
97. Raine AE, Margreiter R, Brunner FP, Ehrich JH, Geerlings W, Landais P, et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992;7 (Suppl 2):7-35.
98. Meyer KB, Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: report from the National Kidney Foundation Task Force on cardiovascular disease. J Am Soc Nephrol 1998;9 (12 Suppl):S31-42.
99. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.
100. Ansari A, Kaupke CJ, Vaziri ND, Miller R, Barbari A. Cardiac pathology in patients with end-stage renal disease maintained on hemodialysis. Int J Artif Organs 1993;1631-6.
101. Vincenti F, Amend WJ, Abele J, Feduska NJ, Salvatierra O, Jr. The role of hypertension in hemodialysis-associated atherosclerosis. Am J Med 1980;68:363-9.
102. Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int 1984;25:653-9.
103. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 1998;13:82-8.
104. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000;15:1827-34.
105. Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 2002;32 (Suppl 1):42-9.
106. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002;40:90-103.
107. Kooistra MP, Kersting S, Gosriwatana I, Lu S, Nijhoff-Schutte J, Hider RC, et al. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002;32 (Suppl 1):36-41.
108. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999;14:2680-7.
109. Ziouzenkova O, Asatryan L, Akmal M, Tetta C, Wratten ML, Loseto-Wich G, et al. Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis. J Biol Chem 1999;274:18916-24.
110. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-13.
111. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002;106: 2212-7.
112. Morrison HI, Semenciw RM, Mao Y, Wigle DT. Serum iron and risk of fatal acute myocardial infarction. Epidemiology 1994;5:243-6.
113. Campbell MJ, Elwood PC, Mackean J, Waters WE. Mortality, haemoglobin level and haematocrit in women. J Chronic Dis 1985;38:881-9.
114. Bottiger LE, Carlson LA. Hemoglobin, plasma lipids, and coronary heart disease. Am Heart J 1973;86:842-4.
115. Sempos CT, Looker AC, Gillum RF, Makuc DM. Body iron stores and the risk of coronary heart disease. N Engl J Med 1994;330:1119-24.
116. Ascherio A, Willett WC, Rimm EB, Giovannucci EL, Stampfer MJ. Dietary iron intake and risk of coronary disease among men. Circulation 1994;89:969-74.
117. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med 1974; 290:1213-6.
118. Cook JD, Lipschitz DA, Miles LE, Finch CA. Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr 1974;27:681-7.
119. Milman N, Pedersen NS, Visfeldt J. Serum ferritin in healthy Danes: relation to marrow haemosiderin iron stores. Dan Med Bull 1983;30:115-20.
120. Magnusson B, Bjorn-Rassmussen E, Hallberg L, Rossander L. Iron absorption in relation to iron status. Model proposed to express results to food iron absorption measurements. Scand J Haematol 1981;27:201-8.
121. Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol 1973;26:770-2.
122. Harmatz P, Butensky E, Quirolo K, Williams R, Ferrell L, Moyer T, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000;96:76-9.
123. Burke W, Reyes M, Imperatore G. Hereditary haemochromatosis: a realistic approach to prevention of iron overload disease in the population. Best Pract Res Clin Haematol 2002;15:315-28.
124. Ludwig J. The nomenclature of chronic active hepatitis: an obituary. Gastroenterology 1993;105:274-8.
125. Lauffer RB. Iron stores and the international variation in mortality from coronary artery disease. Med Hypotheses 1990;35:96-102.
126. Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003;101:15-9.
127. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-8.
128. Ranke C, Hecker H, Creutzig A, Alexander K. Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation 1993;87:1873-9.
129. Schwarz KB, Arey BJ, Tolman K, Mahanty S. Iron chelation as a possible mechanism for aspirin-induced malondialdehyde production by mouse liver microsomes and mitochondria. J Clin Invest 1988;81:165-70.
130. Woollard AC, Wolff SP, Bascal ZA. Antioxidant characteristics of some potential anticataract agents. Studies of aspirin, paracetamol, and bendazac provide support for an oxidative component of cataract. Free Radic Biol Med 1990; 9:299-305.
131. Aruoma OI, Halliwell B. The iron-binding and hydroxyl radical scavenging action of anti-inflammatory drugs. Xenobiotica 1988;18:459-70.
132. Podhaisky HP, Abate A, Polte T, Oberle S, Schroder H. Aspirin protects endothelial cells from oxidative stress -possible synergism with vitamin E. FEBS Lett 1997;417:349-51.
133. Oberle S, Polte T, Abate A, Podhaisky HP, Schroder H. Aspirin increases ferritin synthesis in endothelial cells: a novel antioxidant pathway. Circ Res 1998;82:1016-20.
134. Shi X, Ding M, Dong Z, Chen F, Ye J, Wang S, et al. Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production. Mol Cell Biochem 1999;199:93-102.
135. Fields M, Lewis CG, Bureau I. Aspirin reduces blood cholesterol in copper-deficient rats: a potential antioxidant agent? Metabolism 2001;50:558-61.
136. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793-8.
137. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998;97:716-20.
138. Black DA, Fraser CM. Iron deficiency anaemia and aspirin use in old age. Br J Gen Pract 1999;49:729-30.
139. Fleming DJ, Jacques PF, Massaro JM, D'Agostino RB, Sr., Wilson PW, Wood RJ. Aspirin intake and the use of serum ferritin as a measure of iron status. Am J Clin Nutr 2001;74: 219-26.
140. Salonen JT, Korpela H, Nyyssonen K, Porkkala E, Tuomainen TP, Belcher JD, et al. Lowering of body iron stores by blood letting and oxidation resistance of serum lipoproteins: a randomized cross-over trial in male smokers. J Intern Med 1995;237:161-8.
141. van Jaarsveld H, Pool GF. Beneficial effects of blood donation on high density lipoprotein concentration and the oxidative potential of low density lipoprotein. Atherosclerosis 2002;161:395-402.
142. Meyers DG, Strickland D, Maloley PA, Seburg JK, Wilson JE, McManus BF. Possible association of a reduction in cardiovascular events with blood donation. Heart 1997;78: 188-93.
143. Salonen JT, Tuomainen TP, Salonen R, Lakka TA, Nyyssonen K. Donation of blood is associated with reduced risk of myocardial infarction. The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol 1998;148:445-51.
144. Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion 2002;42: 1135-9.
145. Ascherio A, Rimm EB, Giovannucci E, Willett WC, Stampfer MJ. Blood donations and risk of coronary heart disease in men. Circulation 2001;103:52-7.
146. Zacharski LR, Chow B, Lavori PW, Howes PS, Bell MR, DiTommaso MA, et al. The iron (Fe) and atherosclerosis study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. Am Heart J 2000;139:337-45.
147. Facchini FS, Saylor KL. Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients. Ann N Y Acad Sci 2002;967:342-51.
148. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999;85:753-66.
149. Pratico D, Pasin M, Barry OP, Ghiselli A, Sabatino G, Iuliano L, et al. Iron-dependent human platelet activation and hydroxyl radical formation: involvement of protein kinase C. Circulation 1999;99:3118-24.
150. Halliwell B. Use of desferrioxamine as a 'probe' for iron-dependent formation of hydroxyl radicals. Evidence for a direct reaction between desferal and the superoxide radical. Biochem Pharmacol 1985;34:229-33.
151. Nitenberg A, Paycha F, Ledoux S, Sachs R, Attali JR, Valensi P. Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors. Circulation 1998;97:736-43.
152. Hattori N, Schnell O, Bengel FM, Rihl J, Nekolla SG, Drzezga AE, et al. Deferoxamine improves coronary vascular responses to sympathetic stimulation in patients with type 1 diabetes mellitus. Eur J Nucl Med Mol Imaging 2002;29: 891-8.
153. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF, Jr., et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 2001;103:2799-804.
154. Chekanov VS, Nikolaychik V. Iron contributes to endothelial dysfunction in acute ischemic syndromes. Circulation 2002;105:E35.
155. Hashimoto I, Nakanishi H, Shono Y, Tanaka S. The effects of desferrioxamine on thrombus formation in injured microvessels of the rabbit ear. J Med Invest 1999;46:200-4.
156. Prass K, Ruscher K, Karsch M, Isaev N, Megow D, Priller J, et al. Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J Cereb Blood Flow Metab 2002;22:520-5.
157. Zheng H, Dimayuga C, Hudaihed A, Katz SD. Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects. Arterioscler Thromb Vasc Biol 2002; 22:E15-8.
158. Arthur AS, Fergus AH, Lanzino G, Mathys J, Kassell NF, Lee KS. Systemic administration of the iron chelator deferiprone attenuates subarachnoid hemorrhage-induced cerebral vasospasm in the rabbit. Neurosurgery 1997;41: 1385-91; discussion 1391-2.
159. Matthews AJ, Vercellotti GM, Menchaca HJ, Bloch PH, Michalek VN, Marker PH, et al. Iron and atherosclerosis: inhibition by the iron chelator deferiprone (L1). J Surg Res 1997;73:35-40.